Alphamab Oncology (9966) Stock Statistics & Valuation Metrics

Alphamab Oncology has a market cap or net worth of HK$8.21B. The enterprise value is HK$7.06B.

Alphamab Oncology has 974,293,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Alphamab Oncology’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -8.06%.

The current PE Ratio of Alphamab Oncology is ―. Alphamab Oncology’s PEG ratio is 0.45.

In the last 12 months, Alphamab Oncology had revenue of 551.58M and earned -110.99M in profits. Earnings per share was -0.12.

In the last 12 months, operating cash flow was -104.71M and capital expenditures -31.84M, giving a free cash flow of -136.54M billion.

Alphamab Oncology pays an annual dividend of ―, resulting in a dividend yield of ―

Alphamab Oncology upcoming earnings date is Aug 20, 2026, TBA (Not Confirmed).

Alphamab Oncology as a current ratio of 5.67, with Debt / Equity ratio of 7.19%

In the past 12 months, Alphamab Oncology has paid 0.00 in taxes.

Alphamab Oncology EV to EBITDA ratio is -96.47, with an EV/FCF ratio of -54.25.

Alphamab Oncology has HK$1.35B in cash and marketable securities with HK$123.03M in debt, giving a net cash position of HK$1.23B billion.

Gross margin is 83.01%, with operating margin of -27.07%, and net profit margin of -20.12%.

The average price target for Alphamab Oncology is HK$9.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy